Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis
Abstract
Background and purpose: Episodic migraine is a neurological disorder characterized by recurrent, unilateral headaches that significantly impair quality of life. CGRP monoclonal antibodies, targeting calcitonin gene-related peptide (CGRP), have shown efficacy in preventing and treating episodic migraine.
Methods: A systematic search of PubMed, Cochrane, and Embase databases was conducted in September 2024 to identify randomized controlled trials (RCTs) on CGRP monoclonal antibodies for episodic migraine. A network meta-analysis was performed to assess efficacy (change in monthly migraine days) and safety (incidence of adverse events). Odds ratios (ORs) and surface under the cumulative ranking curve (SUCRA) were calculated.
Results: 16 studies with 9,123 participants were included. galcanezumab (240 mg) showed the highest efficacy (SMD = 0.5012, p < 0.0001). fremanezumab (225 mg) had the highest odds of ≥ 50% reduction in migraine days (OR = 3.1684, p < 0.0001). erenumab (28 mg) showed the best safety profile (OR = 0.6815, p = 0.2220). fremanezumab ranked highest in both efficacy (SUCRA = 84.6%) and safety (SUCRA = 61.8%).
Conclusion: fremanezumab offers the best balance of efficacy and safety. Further long-term studies are needed.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 9,123 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.